Equities research analysts expect Wave Life Sciences Ltd (NASDAQ:WVE) to report ($1.00) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Wave Life Sciences’ earnings, with estimates ranging from ($1.06) to ($0.94). Wave Life Sciences posted earnings of ($0.79) per share in the same quarter last year, which would suggest a negative year over year growth rate of 26.6%. The firm is expected to announce its next earnings report on Thursday, March 15th.
According to Zacks, analysts expect that Wave Life Sciences will report full year earnings of ($3.76) per share for the current fiscal year, with EPS estimates ranging from ($3.82) to ($3.68). For the next financial year, analysts anticipate that the firm will report earnings of ($3.88) per share, with EPS estimates ranging from ($4.52) to ($2.83). Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Wave Life Sciences.
A number of equities research analysts have recently weighed in on the company. BidaskClub upgraded Wave Life Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. TheStreet upgraded Wave Life Sciences from a “d+” rating to a “c-” rating in a research report on Friday, January 5th. Leerink Swann restated an “outperform” rating and set a $53.00 price target (up from $42.00) on shares of Wave Life Sciences in a research report on Wednesday, November 15th. Finally, Mizuho set a $34.00 price target on Wave Life Sciences and gave the company a “buy” rating in a research report on Saturday, October 21st. Two equities research analysts have rated the stock with a sell rating and six have given a buy rating to the stock. Wave Life Sciences currently has a consensus rating of “Buy” and a consensus target price of $41.60.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Nationwide Fund Advisors boosted its position in shares of Wave Life Sciences by 58.1% during the second quarter. Nationwide Fund Advisors now owns 6,720 shares of the company’s stock valued at $125,000 after purchasing an additional 2,470 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Wave Life Sciences by 71.0% in the second quarter. The Manufacturers Life Insurance Company now owns 9,422 shares of the company’s stock worth $175,000 after acquiring an additional 3,912 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in Wave Life Sciences by 64.9% in the second quarter. New York State Common Retirement Fund now owns 12,700 shares of the company’s stock worth $236,000 after acquiring an additional 4,999 shares in the last quarter. Alliancebernstein L.P. bought a new stake in Wave Life Sciences in the second quarter worth $236,000. Finally, Parametric Portfolio Associates LLC bought a new stake in Wave Life Sciences in the second quarter worth $311,000. Institutional investors own 73.60% of the company’s stock.
Shares of Wave Life Sciences (NASDAQ WVE) opened at $42.30 on Wednesday. The firm has a market capitalization of $1,180.00 and a P/E ratio of -11.95. Wave Life Sciences has a 1 year low of $15.15 and a 1 year high of $42.65. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.50 and a quick ratio of 11.50.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2018/02/14/zacks-brokerages-anticipate-wave-life-sciences-ltd-wve-will-announce-earnings-of-1-00-per-share.html.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.